FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
Domestic Manufacturing CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of industrial chemicals in medical devices Drug shortages and supply chain resilience
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| STU EVENHAUGEN | — |
| CHRISTOPHER LEIBUNDGUTH | — |
Copyright/Patent/Trademark CPT
S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) PTAB Proposed Rule - Discretionary Denials and One and Done Ancillary Product Patent Reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | — |
| STEVEN CHASE WALKER | — |
Taxation/Internal Revenue Code TAX
Tax incentives for Onshoring Domestic Manufacturing of Essential Medicines
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER LEIBUNDGUTH | — |
Trade (domestic/foreign) TRD
S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act Section 301 Investigation re: Germany Issues Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines PTAB Proposed Rule - Discretionary Denials and One and Done Federal Procurement Preferences for Domestic Medicines Drug Shortages and Supply Chain Resilience
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| SARAH CHRISTINE D'ORSIE | — |
| STU EVENHAUGEN | — |
| CHRISTOPHER LEIBUNDGUTH | — |
Medicare/Medicaid MMM
S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Drug Shortages and Supply Chain Resilience PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| SARAH CHRISTINE D'ORSIE | — |
| STU EVENHAUGEN | — |
| CHRISTOPHER LEIBUNDGUTH | — |
Health Issues HCR
S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act PTAB Proposed Rule - Discretionary Denials and One and Done Domestic Production of Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of Industrial Chemicals in Medical Devices Drug Shortages and Supply Chain Resilience Employee Benefits Security Administration (EBSA) Proposed Rule Re: Broker/Consultant Transparency to Employer Plans Section 301 Investigation re: Germany Issues PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| SARAH CHRISTINE D'ORSIE | — |
| STU EVENHAUGEN | — |
| CHRISTOPHER LEIBUNDGUTH | — |
| STEVEN CHASE WALKER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.